HCPCS Level II code Q0139 denotes a 1 mg unit of ferumoxytol given by injection for the treatment of iron deficiency anemia in patients with end-stage renal disease receiving dialysis. This code is clinically significant because intravenous iron therapy is a core component of anemia management in dialysis-dependent patients; accurate coding affects clinical documentation, payment, and care coordination across dialysis centers and outpatient infusion settings. Nationally, use of ferumoxytol influences drug utilization patterns and cost for chronic kidney disease care pathways.

Key payers addressed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of clinical context for ferumoxytol in ESRD on dialysis, common billing considerations for infusion services in dialysis clinics, and a summary of payer coverage landscapes where available. The publication outlines typical sites of service and the service type tied to Q0139, and identifies common modifiers provided in the input. Where specific payer policies, fee benchmarks, or related codes are not provided, the text notes that data is not available in the input. This piece is intended to inform billing managers, compliance staff, and clinicians about the coding and administrative context for ferumoxytol injections in dialysis care.